Suche

letzte 3 Monate
43472 Ergebnisse
Dihydroergocristine-Annex_2_first_published_140217.pdf
Annex II Scientific conclusions and grounds for variation to the terms of the marketing authorisations or suspension of the marketing authorisations, as applicable, taking into consideration the
15.12.2017 Datei PD
Dihydroergocristine-Annex_4-Conditions_first_published_140217.pdf
Annex IV Conditions for lifting the suspension of the marketing authorisation 13 Conditions for lifting the suspension of the marketing authorisation National Competent Authoritie
15.12.2017 Datei PD
Dihydroergocryptine-Annex_2_first_published_140217.pdf
Annex II Scientific conclusions and grounds for variation to the terms of the marketing authorisations or suspension of the marketing authorisations, as applicable, taking into consideration the
15.12.2017 Datei PD
Dihydroergocryptine-Annex_4_first_published_140217.pdf
Annex IV Conditions for lifting the suspension of the marketing authorisation 10 11 Conditions for lifting the suspension of the marketing authorisation National Competent Aut
15.12.2017 Datei PD
Dihydroergotamine-Annex_2_first_published_140217.pdf
Annex II Scientific conclusions and grounds for variation to the terms of the marketing authorisations or suspension of the marketing authorisations, as applicable, taking into consideration the
15.12.2017 Datei PD
Dihydroergotamine-Annex_4_first_published_140217.pdf
Annex IV Conditions for the lifting of the marketing authorisation 18 Conditions for the lifting of the suspension of the Marketing Authorisations National Competent Authoritie
15.12.2017 Datei PD
Dihydroergotoxine-Annex_2_first_published_140217.pdf
Annex II Scientific conclusions and grounds for variation to the terms of the marketing authorisations or suspension of the marketing authorisations, as applicable, taking into consideration the
15.12.2017 Datei PD
Dihydroergotoxine-Annex_4_first_published_140217.pdf
Annex IV Conditions for lifting the suspension of the marketing authorisation 18 Conditions for lifting the suspension of the marketing authorisation National Competent Authori
15.12.2017 Datei PD
Nicergoline-Annex_2_first_published_140217.pdf
Annex II Scientific conclusions and grounds for variation to the terms of the marketing authorisations or suspension of the marketing authorisations, as applicable, taking into consideration the
15.12.2017 Datei PD
Nicergoline-Annex_4_first_published_140217.pdf
Annex IV Conditions for lifting the suspension of the marketing authorisation 17 Conditions for lifting the suspension of the marketing authorisation National Competent Authoritie
15.12.2017 Datei PD
Zeichenfläche 1